XML 58 R29.htm IDEA: XBRL DOCUMENT v3.20.4

Collaboration Agreements and Revenues (Tables)

12 Months Ended

Dec. 31, 2020

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

Product revenue, net was as follows (in thousands):

		Years Ended December 31,
		2020				2019
Gross revenue		$	89,027			$	2,803
Price adjustment			—				(936	)
Non-key account hospital listing award			(9,325	)			—
Contractual sales rebate			(6,189	)			(149	)
Other discounts and rebates			(923	)			(18	)
Sales return			(92	)			—
Product revenue, net		$	72,498			$	1,700

Roll-forward of Related Contract Liabilities

. The following table includes a roll-forward of the related contract liabilities (in thousands):

		Balance at December 31, 2019				Additions				Deduction				Currency Translation and Other				Gross Contract Liabilities Balance				Balance Presented Net Against Accounts Receivable				Balance at December 31, 2020
Product revenue - Contract liabilities		$	(1,102	)		$	(16,497	)		$	2,184			$	(270	)		$	(15,685	)		$	548			$	(15,137	)

Schedule of Drug Product Revenue

Drug product revenue was as follows (in thousands):

		Years Ended December 31,
		2020				2019				2018
Astellas		$	4,281			$	(36,324	)		$	64,776
AstraZeneca			4,625				—				—
Drug product revenue		$	8,906			$	(36,324	)		$	64,776

Drug Product Revenue [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related contract liabilities (in thousands):

		Balance at December 31, 2019				Additions				Balance at December 31, 2020
Drug product revenue - Astellas - contract liabilities		$	—			$	(5,984	)		$	(5,984	)

Japan [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2020				2019				2018
Japan		License revenue		$	14,323			$	11,935			$	14,323
		Development revenue		$	1,220			$	1,222			$	2,400

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

Japan Agreement		Cumulative Revenue Through December 31, 2020				Deferred Revenue at December 31, 2020				Total Consideration Through December 31, 2020
License		$	100,347			$	—			$	100,347
Development revenue			16,350				130				16,480
Total license and development    revenue		$	116,697			$	130			$	116,827

Europe [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2020				2019				2018
Europe		License revenue		$	—			$	117,470			$	—
		Development revenue		$	17,954			$	28,172			$	18,503

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):

Europe Agreement		Cumulative Revenue Through December 31, 2020				Deferred Revenue at December 31, 2020				Total Consideration Through December 31, 2020
License		$	487,951			$	—			$	487,951
Development revenue			248,962				1,429				250,391
Total license and development    revenue		$	736,913			$	1,429			$	738,342

U.S./RoW and China [Member]

Summary of License Revenue and Development Revenue Recognized under Agreement

Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):

				Years Ended December 31,
Agreement		Performance Obligation		2020				2019				2018
U.S. / RoW and China		License revenue		$	—			$	47,681			$	7,946
		Development revenue			61,508				84,629				104,970
		China performance obligation		$	(90	)		$	90			$	—

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

U.S. / RoW and China Agreements		Cumulative Revenue Through December 31, 2020				Deferred Revenue at December 31, 2020				Total Consideration Through December 31, 2020
License		$	341,844			$	—			$	341,844
Co-development, information sharing &   committee services			554,775				2,276				557,051
China performance obligation			—				137,338				137,338
Total license and development    revenue		$	896,619			$	139,614		*	$	1,036,233

* Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $137.5 million related to the U.S./RoW and China Agreement, which represents the net of $139.6 million of deferred revenue presented above and a $2.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.

X

- Definition

Contract with customer milestone method.

+ References

No definition available.

+ Details

Name:	fgen_ContractWithCustomerMilestoneMethodTableTextBlock
Namespace Prefix:	fgen_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of drug product revenue.

+ References

No definition available.

+ Details

Name:	fgen_ScheduleOfDrugProductRevenueTableTextBlock
Namespace Prefix:	fgen_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: